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Summary
Bone marrow-derived cells contribute to tumor angiogenesis. Here, we demonstrate that monocytes expressing the Tie2
receptor (Tie2-expressing monocytes [TEMs]) (1) are a distinct hematopoietic lineage of proangiogenic cells, (2) are selec-
tively recruited to spontaneous and orthotopic tumors, (3) promote angiogenesis in a paracrine manner, and (4) account
for most of the proangiogenic activity of myeloid cells in tumors. Remarkably, TEM knockout completely prevented human
glioma neovascularization in the mouse brain and induced substantial tumor regression. Besides TEMs and endothelial
cells (ECs), Tie2 expression distinguished a rare population of tumor stroma-derived mesenchymal progenitors represent-
ing a primary source of tumor pericytes. Therefore, Tie2 expression characterizes three distinct cell types required for
tumor neovascularization: ECs, proangiogenic cells of hematopoietic origin, and pericyte precursors of mesenchymal
origin.S I G N I F I C A N C E
The role of BM-derived cells in angiogenesis is the subject of intense scrutiny and controversy. We show that a distinct lineage of
proangiogenic monocytes exists in the BM and peripheral blood that express Tie2, an angiopoietin receptor previously supposed
to be restricted to ECs and hematopoietic stem cells (HSCs). These proangiogenic cells, and not BM-derived endothelial progenitors
(EPCs), had a requisite role in the vascularization and growth of a clinically relevant tumor model. Our findings support the paradigm
that BM-derived cells recruited to tumors, rather than providing building blocks for postnatal vasculogenesis, comprise a functionally
distinct myeloid lineage of paracrine inducers of angiogenesis. The proangiogenic cells should represent a promising target of novel
anticancer therapies.Introduction
Angiogenesis, the induction and growth of new blood vessels,
is a rate-limiting step for tumor growth (Carmeliet and Jain,
2000). In angiogenesis, new blood vessels originate from the
preexisting vasculature through the proliferation of endothelial
cells (ECs), which maintain a high clonogenic potential throughout
adulthood, and the recruitment of vascular mural cells (Jain,
2003). Besides the origin of tumor ECs from preexisting ves-
sels, it has been proposed that endothelial progenitor cells
(EPCs) exist in the adult bone marrow (BM), circulate in the
peripheral blood (PB), and may incorporate into new blood
vessels (Rafii and Lyden, 2003; Urbich and Dimmeler, 2004;
Khakoo and Finkel, 2005). The existence of a BM reservoir of
EPCs and their selective involvement in neovascularization has
attracted interest because these cells may represent a novel
target for therapeutic intervention. However, although EPCs
were shown to contribute to the blood vessels of certain exper-CANCER CELL : SEPTEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEimental tumors, the general importance of these cells in tumor
angiogenesis remains controversial (Jain and Duda, 2003; Lut-
tun and Carmeliet, 2004). A consensus on the identity and bio-
logical activity of EPCs is still lacking. Some studies have de-
fined EPCs as cells that (1) are mobilized from the BM in
response to cytokine treatment, ischemia, vascular injury, and
tumor growth; (2) express surface markers of both ECs and
hematopoietic progenitor cells (HPCs); (3) can be distinguished
from mature circulating ECs (CECs) by the expression of the
stem cell markers AC133 and c-kit, and by their outgrowth po-
tential in in vitro clonogenic assays; and (4) integrate within the
endothelium of blood vessels as bona fide ECs (Rafii and Ly-
den, 2003). Other studies have reported that EPCs coexpress
EC and mature hematopoietic cell (HC) markers, including
monocyte and dendritic cell markers, and localize both within
the endothelium of blood vessels and extravascularly (Urbich
and Dimmeler, 2004). It is not clear whether EPCs originate in
the BM from primitive (hemo)angioblasts and are immatureR INC. DOI 10.1016/j.ccr.2005.08.002 211
A R T I C L Ecells possibly related to hematopoietic stem cells (HSCs),
rather than differentiating from lineage-committed HCs, such
as monocytes, which can acquire an EC-like phenotype in vitro
and in vivo under angiogenic conditions (Schmeisser et al.,
2001). Moreover, CECs, believed to originate from sloughing of
vessel walls, may substantially contribute to the EPC pool (Lin
et al., 2000).
The functional importance of EPCs in tumor vascularization
was underscored in a study that used the angiogenesis-defec-
tive Id mutant mice. Replacement of Id mutant BM by wild-
type BM cells restored angiogenesis and tumor growth in these
mice (Lyden et al., 2001). However, the extent to which EPCs
contributed to the generation of the tumor endothelium has
been highly variable in different studies, from substantial (Ly-
den et al., 2001), to low and dependent on the tumor type and
grade (Ruzinova et al., 2003; Li et al., 2004; Peters et al., 2005),
to negligible (De Palma et al., 2003a; Machein et al., 2003;
Gothert et al., 2004; Rajantie et al., 2004; Shinde Patil et al.,
2005), possibly due to differences in the experimental models
and the technical difficulty of distinguishing tightly juxtaposed
periendothelial and bona fide ECs in tissues by light micros-
copy.
Besides EPCs, it has been demonstrated that the HCs re-
cruited to tumors play a crucial role in angiogenesis and tumor
progression (Coussens and Werb, 2002; Pollard, 2004). My-
eloid lineage HCs, such as tumor-associated macrophages
(TAMs), can stimulate angiogenesis by secreting angiogenic
factors, or indirectly by producing extracellular matrix-degrad-
ing proteases, which in turn release sequestered angiogenic
factors. This function was highlighted in a mouse model of skin
tumorigenesis, which showed a decreased incidence of inva-
sive cancer upon inactivation of the MMP9 gene. Transplanta-
tion of wild-type BM cells restored tumor development in these
mice (Coussens et al., 2000). Genetic deletion of the CSF-1
gene (Csf1op/op) significantly attenuated the development of in-
vasive carcinomas in tumor-prone transgenic mice, a pheno-
type associated with the failure to recruit macrophages into
neoplastic tissues in the absence of CSF-1 (Lin et al., 2001). In
one study, CD11b+Gr-1+ myeloid cells obtained from the spleens
of tumor-bearing mice were shown to promote angiogenesis
when coinjected with tumor cells; interestingly, deletion of
MMP9 in these cells abolished their tumor-promoting ability
(Yang et al., 2004). Of note, TAMs and CD11b+ myeloid cells
are overlapping and functionally heterogeneous cell popula-
tions, and it would be desirable to know whether their proan-
giogenic activity in tumors is associated with a distinct subset
of these cells. Thus, whereas all these studies underscored the
general importance of BM-derived myeloid cells in tumor an-
giogenesis, little characterization of the specific activity of the
different hematopoietic subsets involved in these processes
has been provided.
We recently identified a small subset of CD11b+ myeloid tu-
mor-infiltrating cells characterized by the expression of the Tie2
angiopoietin receptor (Tie2-expressing monocytes [TEMs]; De
Palma et al., 2003a). Here, by using a combination of genetic
approaches, transplantation strategies, and stringent models
of oncogenesis, we investigated the origin, phenotype, func-
tional role, and relevance of TEMs in tumor angiogenesis. Our
findings provide novel insight into the cellular mechanisms of212tumor vessel formation and have implications for the design of
anticancer therapies.
Results
Tie2 expression in the tumor stroma
To identify the cell types that express Tie2 in tumors, we gener-
ated transgenic mice expressing GFP [TgN(Tie2-GFP)] under
the control of a lentiviral vector (Tie2p/e LV; De Palma et al.,
2003b) containing transcription regulatory sequences of the
Tie2/Tek gene (Jones et al., 2001). We injected the LV into the
perivitelline space of fertilized oocytes, as described (Lois et
al., 2002 and the Supplemental Experimental Procedures in the
Supplemental Data available with this article online) and se-
lected mouse lines carrying multiple vector copies per genome
to amplify detection of Tie2 transcriptional activity. GFP immu-
nofluorescence (IF) staining showed robust and EC-specific
expression of GFP in all organs of TgN(Tie2-GFP) mice (n = 9),
including heart, liver, brain, gut, and spleen (Figure S1).
We then analyzed N202 mouse mammary tumors grown
subcutaneously (s.c.) and found that GFP was expressed in the
majority of vascular ECs (CD31+ and CD34+; Figure 1A and
data not shown) and by a small fraction of tumor-infiltrating
leukocytes, identified as TEMs (CD45+; Figure 1A). Fluores-
cence-activated cell sorting (FACS) of tumors made into single-
cell suspensions showed that the Tie2-GFP+ cells were uni-
formly Tie2+ and Sca-1+ and accounted for 1%–2% of the total
cells (Figure 1B). The majority of the tumor-derived Tie2-GFP+
cells were ECs (Tie2+CD31+CD45−), whereas w5% were iden-
tified as Tie2+CD11b+CD45+ TEMs. These TEMs, which ex-
pressed Sca-1, were c-kit−. Interestingly, a significant fraction
of tumor-derived Tie2-GFP+ cells were Tie2+CD31−CD45−; the
identity of these cells will be discussed below. In summary,
three distinct cell populations expressed Tie2 in tumor grafts:
vascular ECs, hematopoietic TEMs, and a population of stro-
mal cells distinct from ECs and HCs (see Table S1 for a list of
markers expressed by these cell populations).
Tie2 expression in the hematopoietic system
We analyzed GFP expression in the BM and PB of TgN(Tie2-
GFP) mice (Figures 1C and 1D, Table S1, and Figure S2). Two
to five percent of BM cells were Tie2-GFP+ (Figure 1C). FACS
analysis showed that these Tie2-GFP+ cells were ECs (<5%
CD31+CD45−; data not shown) and HCs (>95% CD45+). The
Tie2-GFP+ HCs were enriched in Sca-1+ (w30%) and c-kit+
(w50%) progenitors. Colony-forming cell (CFC) assays of
sorted cells showed that the Tie2-GFP+ fraction of c-kit+CD45+
BM cells did not form colonies, in contrast to the Tie2-GFP−
fraction, which gave 10% outgrowth, suggesting that Tie2 ex-
pression was associated with the more primitive HPCs/HSCs
(data not shown). In agreement with this notion, we showed
that Tie2 receptor+ HCs were highly enriched in the BM HSC
fraction of wild-type mice (Figure S2). Interestingly, the Tie2-
GFP+ HCs of the BM of TgN(Tie2-GFP) mice also contained a
population of myeloid lineage (CD45+CD11b+) cells (Figure 1C).
These cells were distinct from committed progenitors, because
they did not form colonies in CFC assays (data not shown).
Thus, in the BM, Tie2 was expressed by ECs and putative
HSCs, as shown in previous studies (Yano et al., 1997; Arai et
al., 2004), and by a subset of myeloid lineage cells distinct
from HPCs.CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 1. Tie2 expression in tumors and in the hematopoietic system of Tie2-GFP transgenic mice
A: Confocal IF analysis of N202 tumors shows GFP expression (green) in CD31+ ECs (red) and in CD45+ TEMs (arrows; red). Nuclei labeled by TO-PRO-3 (TP3;
blue). Scale bar, 120 m.
B: Tumor FACS analysis. All GFP+ cells expressed Tie2 and Sca-1 (dot plots on the left). The Tie2+GFP+ cells (density plots on the right) were CD45+CD11b+
TEMs (Ba), CD45−CD31+ ECs (Bb), or CD45−CD31− cells (Bc). The Tie2+GFP+CD45+ TEMs were c-kit−.
C: BM FACS analysis. The GFP+ cells (dot plots on the left) were enriched in Sca-1+ cells (open histogram; filled histogram is the IgG isotype control) and
CD45+c-kit+ cells. GFP was also expressed by CD45+CD11b+ myeloid cells (density plots on the right).
D: PB FACS analysis. The GFP+ cells were monocytes (dot plots on the bottom left; L, lymphocytes; M, monocytes; G, granulocytes) and were mostly
CD45+CD11b+/CD45+c-kit−/CD45+CD31− myeloid lineage hematopoietic TEMs (density plots on the right).In the PB (Figure 1D), a small fraction (w1%–2%) of the leu-
kocytes were identified as TEMs (Tie2-GFP+). These circulating
TEMs were 99% CD45+ and >85% CD11b+, accounted for ap-
proximately 10% of the total myeloid CD11b+ cells, were dis-
tinct from granulocytes according to light scattering featuresCANCER CELL : SEPTEMBER 2005and the expression of Gr-1, and mostly did not express the
HSC/HPC markers c-kit (95% c-kit−) and Sca-1 (>70% Sca-1−).
TEMs did not express the B cell marker CD19, the T cell marker
CD3, or the pan-NK marker CD49b (Figure S2). In addition,
TEMs were CD31Low (Figure 1D) and VEGFR-2− (Figure S2) and213
A R T I C L EFigure 2. Transplantation of wild-type BM cells does not rescue the angiogenesis-defective phenotype of Tie2-tk transgenic mice
A: N202 tumor growth (average volume ± SEM) in GCV-treated wild-type (n = 5) and Tie2-tk mice (n = 6), and in untreated Tie2-tk mice (n = 6).
B: TUNEL assays of day 5 untreated (−GCV; n = 3) and GCV-treated (+GCV; n = 3) tumors grown in Tie2-tk mice. TUNEL reactivity (red) was scant in tumors
from untreated mice, whereas it was marked in the GFP+ cells (green) of tumors from treated mice. Scale bar, 120 m. A small blood vessel containing a
TUNEL+ EC nucleus is shown in the lower panels (scale bar, 30 m).
C: Tumor FACS analysis of apoptosis/necrosis by annexin V/7-amino-actinomycin D staining. The GFP+CD31+ tumor ECs of untreated mice (n = 3; dot plot
on the top left) contained few double apoptotic/necrotic cells (9% ± 2%; density plot on the top right). There were much fewer GFP+ cells in GCV-treated
mice (<0.1% versus >0.3% in untreated mice; n = 3; p < 0.05; dot plot on the bottom left), and most of the GFP+ ECs were double apoptotic/necrotic
(78% ± 9%; density plot on the right).214 CANCER CELL : SEPTEMBER 2005
A R T I C L Ethe transplant, all recipients were surviving and had normal he-
D: N202 tumor growth (average volume ± SEM) in Tie2-tk mice transplanted with wild-type BM cells and treated with GCV starting at the indicated time
after tumor challenge, or left untreated (n = 5 for each group).
E: Photos of tumors grown in mice treated from day 8 as in D, or left untreated, and excised at day 25.
F: CD31 IF staining (red) of representative tumors from E. Scale bar, 120 m.
of exogenous ECs present in the tumors of treated mice at thethus were distinct from EPCs and CECs. In summary, the phe-
notype of circulating TEMs indicates that they represent a dis-
tinct subset of monocytes.
Generation of conditional angiogenesis-defective,
tumor-resistant transgenic mice
To study the function of the different Tie2+ cell types observed
in tumors, we generated transgenic mice expressing the condi-
tionally toxic gene thymidine kinase (tk) under the control of
the Tie2p/e LV [TgN(Tie2-tk)]. In these mice, GFP expression
was linked to that of tk by an IRES element. The GFP pattern
in TgN(Tie2-tk) mice was similar to that observed in TgN(Tie2-
GFP) mice, although the expression level was weaker because
it was IRES dependent, and labeling with anti-GFP antibodies
was required to detect GFP expression (data not shown).
Five to twelve days after N202 tumor challenge, we treated
TgN(Tie2-tk) mice with GCV daily for 12 days (2.5 mg/mouse)
or left them untreated, and monitored tumor growth for up to
60 days (Figure 2A and data not shown). GCV completely pre-
vented tumor growth in TgN(Tie2-tk) mice (n = 15). Tumor
growth rates were similar in wild-type FVB (n = 5) and untreated
TgN(Tie2-tk) mice (n = 15), indicating that GCV treatment or tk
expression alone had no effect on tumor growth. Interestingly,
the 12 day GCV treatment completely prevented the tumors
from relapsing during the 6–8 week observation time that fol-
lowed the end of the treatment, indicating eradication of the
tumor challenge (data not shown). In some of these experi-
ments, GCV treatment was started as the tumors had reached
a large size (day 12 postinjection). Even in these conditions, all
tumors rapidly regressed (data not shown and Figure 2D).
TUNEL assays performed on tumor sections (Figure 2B) and
FACS of tumors made into single-cell suspensions and ana-
lyzed for cell apoptosis/necrosis by annexin V/7-amino-actino-
mycin D double staining (Figure 2C) revealed substantial EC
apoptosis/necrosis and effective reduction of GFP+ cells in tu-
mors from GCV-treated TgN(Tie2-tk) mice (5 day treatment,
started at day 12 after tumor challenge; n = 3), as compared
to untreated mice (n = 3). These data indicated that tumor re-
sistance in GCV-treated TgN(Tie2-tk) mice was a direct conse-
quence of impaired angiogenesis mediated, at least in part, by
EC death.
Elimination of TEMs without myelosuppression
and without loss of long-term repopulating HSCs
Although Tie2 is likely expressed by HSCs (see above), GCV-
treated TgN(Tie2-tk) mice had normal hematopoiesis for up to
8 weeks after the end of the treatment, the longest time point
analyzed. GCV-treated mice, however, had substantially re-
duced frequency of Tie2-GFP+ cells in the BM and almost no
circulating TEMs in PB. Despite the depletion of the majority of
Tie2-expressing cells, BM cells exposed to GCV in vivo re-
mained capable of radioprotecting lethally irradiated mice in a
BM transplantation (BMT) model (Figure S3). Eight weeks afterCANCER CELL : SEPTEMBER 2005matopoiesis, indicating long-term engraftment of Tie2-tk BM
cells exposed to GCV. These results strongly suggested that
HSCs, even if they expressed Tie2, were resistant to GCV. Fur-
thermore, because elimination of the majority of the BM Tie2-
GFP+ cells did not cause obvious myelotoxicity in GCV-treated
mice, the GCV-sensitive Tie2-GFP+ cells likely represented a
specific lineage of HCs, rather than multipotent HPCs.
Transplantation of wild-type BM cells does not rescue
angiogenesis in angiogenesis-defective transgenic mice
Transplantation of wild-type BM in Tie2-tk transgenic mice
might provide a source of EPCs capable of rescuing the geneti-
cally hampered supply of ECs. To explore this scenario, we
generated Tie2-tk/wtBM chimeras by transplanting wild-type
BM cells into lethally irradiated TgN(Tie2-tk) mice. Engraftment
of long-term repopulating wild-type HSCs was assessed by
CFC assays and PCR for vector sequences 10–12 weeks after
the transplant, showing that w80% (n = 60 CFCs from seven
mice) of the CFCs were of donor origin in the transplanted
mice. Six to eight weeks after the transplant, we injected N202
tumor cells and found that GCV completely prevented tumor
growth in Tie2-tk/wtBM mice (n = 5; Figure 2D). As observed
in nontransplanted TgN(Tie2-tk) mice, the 12 day GCV treat-
ment of Tie2-tk/wtBM mice prevented the tumors from relaps-
ing during the 4–6 week observation time that followed the
treatment (data not shown). To rule out the possibility that BM-
derived wild-type EPCs required an established tumor to be
efficiently mobilized, or a preformed tumor vasculature to con-
tribute to tumor angiogenesis, we also started GCV treatment
8 (n = 5) or 15 (n = 5) days after tumor challenge, when tumors
had reached a large size. GCV induced a rapid regression of
the tumor mass in all treated mice (Figure 2E). The regressing
tumors displayed marked necrosis (data not shown) and drasti-
cally reduced vascular density (Figure 2F), as compared to
those growing in untreated mice. Interestingly, the few blood
vessels observed in regressing tumors had large diameter and
were not branched. Overall, these results indicate that putative
BM-derived EPCs were not capable of rescuing tumor angio-
genesis in GCV-treated Tie2-tk/wtBM mice. Of note, the exper-
imental conditions that were used were biased toward the
mobilization and incorporation of putative donor BM-derived
EPCs into tumor blood vessels by eliminating the competition
from endogenous, host-derived ECs.
A possible caveat of the experiments described above was
that, in GCV-treated mice, tk-expressing ECs might spread
toxicity to neighboring tk-negative cells (“bystander effect”),
possibly affecting the incorporation and survival of putative
BM-derived EPCs into tk-expressing tumor vessels in our
transplantation model. To address this issue, we coinjected
wild-type tumor-derived ECs together with tumor cells in Tie2-
tk transgenic mice and found that the exogenous ECs inte-
grated within the growing tumor vasculature in the presence of
GCV (Figure S4). Interestingly, despite the relatively low amounts215
A R T I C L Etime of analysis, these cells rescued tumor angiogenesis and
growth, in contrast with BM-derived cells that failed to do so
in the BMT experiments described above (Figure S4). Overall,
these data argue against the possibility that tk-mediated by-
stander effect was responsible for the lack of incorporation of
BM-derived EPCs into the vasculature of tk-transgenic mice.
Tumor TEMs promote tumor angiogenesis
To directly assay the proangiogenic activity of tumor TEMs,
we isolated GFP+CD11b+ cells from N202 tumors grown in
TgN(Tie2-GFP) mice by FACS and injected these cells (>95%
purity; Figure S5) together with N202 tumor cells (1:20 ratio;
2.5 × 104 TEMs) in nude mice. As controls, we injected N202
cells alone, and N202 cells with GFP−CD11b+ tumor-derived
myeloid cells, which included all myeloid lineage cells, except
for TEMs. We studied tumor vascularization 6 days postinjec-
tion, when tumors were at an early stage of growth and had a
diameter of 2–3 mm (Figure 3A). We observed scant vasculari-
zation in tumors (n = 3) derived from the injection of N202 cells
alone. In these tumors, CD31+ or CD34+ (Figure 3B) blood ves-
sels were few, had a small diameter, and were little branched.
On the contrary, tumor challenges coinjected with TEMs (n =
3) were much more vascularized, and the blood vessels were
larger and irregularly shaped and had a more developed branch-
ing pattern. Computer-assisted digital image analysis showed
that the overall vascular area was 4-fold higher in tumors coin-
jected with TEMs than in control tumors. Interestingly, tumor
angiogenesis was not enhanced by the coinjection of N202
cells and CD11b+ myeloid cells depleted of TEMs (n = 3).
These results indicated that TEMs have a superior proangio-
genic activity among tumor-infiltrating myeloid cells. We did
not detect GFP+ cells in the tumors 6 days after injection of the
cells, suggesting a rapid turnover of TEMs in growing tumors, a
circumstance that argues against the possibility that these cells
are immature HPCs. Interestingly, all tumors displayed abun-
dant infiltration of both CD45+ hematopoietic cells and NG2+
pericytes/myofibroblasts (Figure 3B), suggesting that these
cells colonize tumors during the early stages of development,
possibly before a functional vasculature has been established,
or in concomitance with the angiogenic switch.
Circulating TEMs promote angiogenesis and are the likely
precursors of tumor TEMs
To explore the relationship between circulating and tumor-
homing TEMs, and to investigate whether commitment to a
proangiogenic function already occurs in circulating cells rather
than being locally induced within the tumor stroma, we purified
TEMs from the PB of TgN(Tie2-GFP) mice by FACS (purity
>95%; Figure S5) and tested their proangiogenic activity in an
in vivo matrigel plug assay. We injected matrigel alone (n = 3),
or matrigel containing freshly isolated TEMs (7 × 104 cells; n =
5), or an equal number of peripheral blood mononuclear cells
(PBMCs) depleted of TEMs (n = 5), or an excess of total
PBMCs (2.5 × 105 cells; n = 2), s.c. in nude mice. We excised
matrigel plugs 8 days later and found that, while matrigel alone
contained few cells, TEMs induced a robust capillary network,
as shown by CD34 immunostaining of matrigel sections (Figure
3C). These CD34+ vascular structures were GFP negative, indi-
cating that they did not originate from the injected cells; how-
ever, a few GFP+CD45+ TEMs, often associated with the de-
veloping vascular network, were still present in the matrigel 8216days postinjection (data not shown). Remarkably, PBMCs de-
pleted of TEMs did not induce significant angiogenesis in mat-
rigel (p < 0.01 versus TEMs), and an excess of total PBMCs
was no more effective than purified TEMs. Thus, PB TEMs had
superior capacity to trigger an early angiogenic response
among PBMCs in the experimental conditions used.
The proangiogenic activity of PB TEMs suggested that these
cells were the likely precursors of tumor TEMs. To further in-
vestigate this relationship, we transplanted wild-type mice with
TgN(Tie2-tk) transgenic BM cells, and 8 weeks later we chal-
lenged them with N202 tumors and administered GCV before
the tumors became visible, in order to eliminate TEMs before
they reached the tumor site. GCV-treated mice (n = 5) showed
a drastically reduced tumor growth as compared with un-
treated mice (n = 5), indicating that elimination of circulating
TEMs was sufficient to inhibit tumor growth (Figure 3D). Inter-
estingly, when we stopped GCV treatment, the tumors re-
mained dormant for more than 2 weeks before resuming their
growth (data not shown), suggesting that reconstitution of the
TEM lineage was required before the tumors could turn on an-
giogenesis and resume their growth. Taken together, these
findings imply that circulating TEMs represent a distinct line-
age of proangiogenic monocytes required to promote vascular
growth in vivo.
Recruitment of TEMs to spontaneously arising mouse
pancreatic tumors and orthotopic xenografts
of human glioblastomas
In order to extend the aforementioned findings to clinically rele-
vant models of oncogenesis, we studied the recruitment of
TEMs to both spontaneously arising pancreatic and orthotopi-
cally growing brain tumors.
In RIP-Tag2 transgenic mice, a fraction of the pancreatic is-
lets spontaneously develops into adenomas/invasive adeno-
carcinomas (Hanahan, 1985). We transplanted newborn RIP-
Tag2 mice with BM lin− cells transduced with either the Tie2p/
e-GFP or the ubiquitously expressed PGKp-GFP LV, to obtain
Tie2-BMT (n = 11) and PGK-BMT (n = 4) RIP-Tag2 mice, re-
spectively. Orthotopically growing brain tumors were induced
by injecting human glioma cells (isolated from glioblastoma
multiforme; Galli et al., 2004) into the right striatum of Tie2-
BMT (n = 8) and PGK-BMT (n = 3) nude mice, which had been
previously transplanted with transduced lin− cells.
RIP-Tag2 mice were euthanized at 12–13 weeks of age,
when the pancreata of all mice contained macroscopic vascu-
larized lesions. Total body irradiation and BMT prolonged the
average mouse survival by 1 to 2 weeks but did not affect the
incidence or progression of adenomas to invasive tumors (data
not shown). IF staining of pancreatic sections obtained from
PGK-BMT mice (hematopoietic chimerism was 81% ± 7%, as
measured by frequency of GFP+ cells in the PB) showed abun-
dant GFP+ cells both throughout the exocrine pancreatic tissue
(Figure 4A) and in the tumors (Figure 4B). In the tumors, virtu-
ally all GFP+ cells were hematopoietic (CD45+; data not shown)
and were mostly CD11b+ or F4/80+ (data not shown) tumor-
infiltrating macrophages. Both the CD31+ or CD34+ ECs and
the α-smooth muscle actin (α-SMA)+ pericytes/smooth muscle
cells (data not shown) were GFP negative, indicating that the
blood vessels of the pancreatic tumors were not BM derived.
In brain tumors grown for 6 weeks in PGK-BMT mice (hemato-
poietic chimerism was 83% ± 12%), more than 85% of the F4/CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 3. Proangiogenic activity of tumor and circulating TEMs
A: Vascular area (histograms showing average fold increase over reference value ± SEM) in tumors originated from the injection of N202 cells (n = 3;
reference value), N202 cells and TEMs (n = 3), or N202 cells and CD11b+ myeloid cells depleted of TEMs (n = 3), and grown for 5 days in nude mice.
Representative pictures of tumor sections immunostained for CD31 (red) and GFP (green) are shown on the bottom. Scale bar, 120 m.
B: Confocal IF analysis for NG2 (green), CD45 or CD34 (red), and TP3 (blue) staining of tumors originated by the injection of N202 cells (left) or N202 cells
and TEMs (right), as in A. Scale bar, 120 m.
C: Average number ± SEM of cell nuclei (black bars) and of nuclei belonging to CD34+ vascular structures (gray bars) per ×200 microscope field in matrigel
sections. Matrigel alone (n = 3), matrigel containing TEMs (n = 5), matrigel containing an excess of PBMCs (n = 2), or matrigel containing PBMCs depleted
of TEMs (n = 5) were injected 8 days earlier s.c. in nude mice. Representative pictures of sections immunostained for CD34 (red) and stained with TP3
(blue) are shown on the bottom. Scale bar, 120 m.
D: N202 tumor growth (average volume ± SEM) in wild-type FVB mice transplanted with transgenic Tie2-tk BM cells 8 weeks earlier, and either treated with
GCV for the indicated time (n = 5) or left untreated (n = 5).80+ monocyte/macrophage lineage cells were GFP+ (>1000 F4/
80+ cells analyzed), whereas in the brain parenchyma only a
small fraction of these cells were GFP+, consistent with the
expected turnover of microglia in noninjured brains (Biffi et al.,
2004) and with an enhanced infiltration of the tumors by mac-
rophages (Figure 4C). In the tumors, all GFP+ cells were
hematopoietic (CD45+ or F4/80+) and did not colocalize with
CD31+ or CD34+ ECs, indicating that the tumor blood vessels
were not BM derived. In addition, the GFP+ cells were α-SMA−,
and virtually all were NG2− (>98%; >250 NG2+ cells analyzed),
indicating that the occurrence, if any, of BM-derived pericytes/
myofibroblasts in brain tumors is extremely rare. Overall, these
data show that transplanted BM cells and their progeny main-CANCER CELL : SEPTEMBER 2005tained hematopoietic lineage fidelity in both spontaneous and
orthotopic tumors and did not adopt vascular cell fates with
significant frequency.
We then studied the recruitment of TEMs to these tumors. In
Tie2-BMT RIP-Tag2 mice, Tie2-GFP+CD11b+ TEMs were se-
lectively present in the pancreatic tumors, and not in the sur-
rounding exocrine tissue or normal islets (Figures 5A and 5B).
These TEMs often had a perivascular location but were CD31−
and CD34− and distinct from vascular ECs (Figure 5B and data
not shown). In the brain of Tie2-BMT nude mice, TEMs were
present within the tumor (Figure 5C) but were never found in
the noninfiltrated brain parenchyma. TEMs were an important
fraction of the total CD45+ HCs found within brain tumors217
A R T I C L EFigure 4. Contribution of BM-derived cells to
spontaneous pancreatic and orthotopic brain
tumors
A and B: GFP (green) and CD11b or CD31 (red)
IF analysis and TP3 (blue) staining of the exo-
crine pancreatic tissue (A) and pancreatic islet
tumors (B) from PGK-BMT RIP-Tag2 mice. The
dashed line indicates the tumor perimeter.
Scale bars, 120 m.
C: GFP (green) and CD45, F4/80, CD31, CD34,
NG2, or α-SMA (red) IF analysis of human or-
thotopic glioblastomas from PGK-BMT nude
mice. Scale bars, 120 m.(average 9% ± 3%; >1000 CD45+ cells analyzed; Figure 5C),
sometimes had a branched morphology, and uniformly ex-
pressed CD11b (data not shown). As observed in pancreatic
tumors, TEMs were CD31− and CD34− and were not integrated
within the EC layers of blood vessels. Many TEMs had a peri-
endothelial location similar to that of pericytes; however, TEMs
did not express NG2 (Figure 5C) and α-SMA (data not shown),
indicating that TEMs are bona fide HCs distinct from pericytes
and smooth muscle cells. Interestingly, both TEMs and NG2+
pericytes had an intriguingly similar perivascular location, but
in NG2+ (“coated”) vessels TEMs had an adluminal position
with respect to the pericyte layer.
TEMs trigger the angiogenic phase in human glioma
orthotopic xenografts
IF staining of brain tumors showed that the wide majority of
TEMs expressed basic fibroblast growth factor (bFGF), a po-
tent proangiogenic molecule (Figure 5D), suggesting that TEMs
might promote angiogenesis via the release of bFGF, and
possibly other proangiogenic factors. We then asked whether
TEMs play a critical role during the angiogenic phase of glioma
development. We transplanted human glioma cells (U87 cells;
Winkler et al., 2004) in the striatum of nude mice, which were
previously transplanted with Tie2-tk transgenic BM-derived lin−
cells. One day after the injection of the tumor cells, we ran-
domly sorted the mice into two groups and left them untreated
(n = 7) or treated them with GCV (2.5 mg/mouse) daily for 12218days (n = 7) in order to eliminate TEMs. Eighteen days later,
we analyzed the tumors by magnetic resonance imaging (MRI),
histology, and IF analysis (Figure 6 and Figure S6). GCV treat-
ment and TEM elimination (see below) did not prevent tumor
take, consistent with the ability of gliomas to initially grow by
coopting the preexisting vasculature. MRI, however, showed
that the treated tumors were on average smaller than the un-
treated tumors and displayed a markedly reduced contrast
(gadolinium) uptake, with mixed hyperintense and hypointense
signal, indicating impaired perfusion and widespread cell loss
(Figure 6A). MRI volumetry indicated that tumor necrosis was
dramatically increased in GCV-treated as compared to un-
treated mice (>10-fold; p < 0.02; n = 5; Figure S6). Consistent
with MRI, hematoxylin/eosin staining of brain sections showed
that GCV-treated gliomas were mostly made of nonviable tis-
sue (Figure 6B). Extensive necrosis was also prevalent at the
tumor margins, a finding in sharp contrast with the untreated
tumors. Moreover, the proliferation index of the GCV-treated tu-
mors was extremely low, as indicated by the paucity of Ki67+
nuclei both in the inner tumor mass and at the tumor margins
(Figure 6C). Taken together, these data strongly suggested that
gliomas of GCV-treated mice were regressing at the time of
analysis.
CD31 IF staining showed that the tumors of GCV-treated
mice were almost avascular, whereas those of untreated mice
were highly angiogenic (Figure 6D). Computer-assisted digital
image analysis indicated that, at the tumor periphery, the totalCANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 5. Contribution of TEMs to spontaneous
pancreatic and orthotopic brain tumors
A and B: GFP (green) and CD11b or CD31 (red)
IF analysis and TP3 (blue) staining of the exo-
crine pancreatic tissue (A) and pancreatic islet
tumors (B) from Tie2-BMT RIP-Tag2 mice. The
dashed line indicates tumor perimeter. Scale
bars, 120 m.
C and D: GFP (green) and CD45, CD31, NG2, or
bFGF (red) IF analysis of human orthotopic gli-
oblastomas from Tie2-BMT nude mice. Scale
bars, 120 m.vascular area was >20-fold lower in the treated mice than in
the untreated (p < 0.01; n = 4) and that the vessel density was
also greatly reduced (34 ± 7 and 141 ± 12 vessels/mm2 in
treated and untreated mice, respectively; p < 0.01; n = 4). Inter-
estingly, the rare blood vessels observed in GCV-treated tu-
mors had regular shape and small diameter, were covered by
NG2+ or α-SMA+ (data not shown) pericytes, and thus likely
represented residual coopted vessels. By contrast, the blood
vessels of control tumors were abnormally enlarged and tortu-
ous, contained many Ki67+ EC nuclei, and had loosely associ-
ated pericytes, all typical features of angiogenesis (Figure 6D).
Thus, GCV treatment severely impaired the angiogenic phase
in orthotopic gliomas.
GCV effectively cleared GFP+ TEMs from tumors but did not
inhibit the recruitment of CD11b+ macrophages and Gr-1+
granulocytes (Figure 6E). Moreover, the large necrotic areas of
treated tumors were heavily infiltrated by these scavenging
cells. Taken together, these results proved the selective action
of the tk/GCV system in our transplantation model and indi-
cated that tumor-infiltrating macrophages and granulocytes
were not able to locally reconstitute the TEM cell pool or surro-
gate their function, supporting the notion that TEMs are a dis-
tinct proangiogenic lineage of HCs required for tumor vascular-
ization.CANCER CELL : SEPTEMBER 2005Mesenchymal progenitors that express Tie2 in tumors
are the likely precursors of vascular pericytes
In addition to ECs and TEMs, a third distinct cell population
expressed Tie2 in tumors. These Tie2+ cells only expressed the
membrane-associated aminopeptidase N (CD13) and Sca-1
among a panel of “mesoderm lineage” markers and accounted
for a sizeable fraction of all tumor Tie2-GFP+ cells (w30%; Fig-
ure 7A). The surface phenotype of these cells (Tie2+CD13+Sca-
1+CD31−CD45−) was reminiscent of that of certain types of
mesenchymal progenitor cells (MPCs), including mesoangio-
blasts (Sampaolesi et al., 2003). In tumor sections (Figure
7B), the Tie2-GFP+CD13+CD31−CD45− cells had an elongated
spindle shape and were mostly found clustered near blood
vessels but did not express the pericyte NG2 and α-SMA (data
not shown) markers.
To investigate the nature of these cells, we isolated Tie2-
GFP+CD13+CD31−CD45− cells from N202 tumors grown in
TgN(Tie2-GFP) mice by cell sorting (purity >98%; Figure S5).
The cells efficiently differentiated into pericyte/smooth muscle-
like, osteoprogenitor-like and, to a lesser extent, adipocyte-like
cells when cultured in vitro under specific growth conditions
(Figure 7C and Supplemental Experimental Procedures). Al-
though the demonstration of multipotency would require clonal
analyses, our results indicate that this cell population is highly
enriched in MPCs.219
A R T I C L EFigure 6. TEMs trigger the angiogenic phase in
human glioma orthotopic xenografts
A: Contrast-enhanced T1-weighted axial (upper
panels) and coronal (lower panels) MRI analy-
ses show that gadolinium uptake is homoge-
neous in the untreated tumor (−GCV; n = 5),
whereas it appears highly inhomogeneous in
the treated one (+GCV; n = 5), indicating the
presence of large areas of tumor cell loss. Note
that the untreated tumor displays widespread
striatal infiltration extending toward the frontal
lobe and leptomeningeal spreading.
B: Hematoxylin/eosin staining of representative
tumor sections from untreated (−GCV; n = 7)
and treated (+GCV; n = 7) mice shows wide-
spread necrosis and massive cell loss in the
treated tumor. Scale bars, 1200 m (upper pan-
els) and 120 m (bottom panels).
C–E: Ki67, NG2, or GFP (green) and CD31,
CD11b, or Gr-1 (red) IF analysis and TP3 (blue)
staining of representative tumor sections from
untreated (−GCV; n = 5–7) and treated (+GCV;
n = 5–7) mice. Arrows indicate Ki67+ EC nuclei;
arrowheads indicate small blood vessels cov-
ered by NG2+ pericytes. Tumor areas with scant
nuclear staining (TP3; blue) reflect tissue necro-
sis. Scale bars, 120 m.We next injected freshly isolated Tie2-GFP+CD13+CD31−
CD45− MPCs together with N202 tumor cells (1:20 ratio; 2.5 ×
104 MPCs) s.c. in nude mice (Figure 7D). We analyzed the tu-
mors 8 days later and found abundant Tie2-GFP+ cells in the
tumor stroma, suggesting that these cells proliferated in vivo
while keeping Tie2 expression on. Although the majority of the
GFP+ cells were associated with blood vessels, they were
CD31− and did not differentiate into ECs. Of note, control pop-
ulations of tumor-derived Tie2-GFP+CD31+CD13−CD45− ECs
efficiently integrated within the endothelium of blood ves-
sels. Furthermore, the wide majority of the Tie2-GFP+ cells did
not express the pericyte markers NG2 and α-SMA (data not
shown), suggesting that these cells maintained an undifferenti-
ated phenotype in vivo at 8 days postinjection. Alternatively, it
is possible that Tie2 (and GFP) expression was shut off upon220differentiation of the cells in vivo. To rigorously track the fate of
Tie2+CD13+ cells in tumors, we crossed Tie2-GFP transgenic
with Rosa26 mice, which express the reporter gene β-galacto-
sidase (β-gal) ubiquitously, and obtained double transgenic
TgN(lacZ/Tie2-GFP) mice (see the Supplemental Experimental
Procedures and Figure S1). MPCs isolated from tumors grown
in these mice could be expanded in culture for >20 cell dou-
blings and were phenotypically characterized by FACS and RT-
PCR analysis of cell surface molecules, growth factors, and
receptors (Figure 8A). In vitro, the cells uniformly expressed
β-gal and maintained an undifferentiated MPC phenotype. In-
deed, the cultured cells continued to express high levels of
Sca-1 and low levels of Tie2 and CD13. Furthermore, RT-PCR
analysis showed that the cells only expressed VEGF-A, bFGF,
HGF, and FGFR-1 among a wide panel of growth factors andCANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 7. Isolation of Tie2+ mesenchymal pro-
genitors from tumors
A: FACS analysis of tumors grown in wild-type
and Tie2-GFP transgenic mice (dot plots on the
left). The GFP+CD13+ cells (gate 1) were
CD45−CD31− cells; the GFP+CD13− cells (gate 2)
were CD45−CD31+ ECs; the GFP−CD13+ cells
(gate 3) contained CD45+CD31− HCs (density
plots on the right).
B: Confocal IF analysis for GFP (green) and
CD31, CD45, or CD13 (red) and TP3 (blue) stain-
ing of N202 tumors grown in Tie2-GFP transgenic
mice shows the presence of CD31− (left), CD45−
(middle), and CD13+ (right) GFP+ cells. Scale
bar, 30 m.
C: Photos of cell cultures derived from purified
GFP+CD13+CD45−CD31− cells (MPCs). Cells
were stimulated to differentiate into α-smooth
muscle actin-positive smooth muscle-like cells,
alkaline phosphatase-positive osteoprogenitor-
like cells, and red oil-positive adipocyte-like
cells, or left unstimulated. The frequency of
marker-positive cells is indicated (average of
two experiments), as assessed by DAPI nuclear
staining (light blue). Control cell populations
were unstimulated MPCs and stimulated embry-
onic fibroblasts and mesoangioblasts.
D: Confocal IF analysis for GFP (green), CD31
(red), and TP3 (blue) staining of tumors origi-
nated by the injection of N202 cells together
with freshly isolated MPCs (left panels) or ECs
(right panel) in nude mice and analyzed 8 days
later. Note that Tie2-GFP+CD31+ ECs, but not
Tie2-GFP+CD13+ MPCs, integrated within tumor
blood vessels (arrows). Both MPCs and ECs were
isolated from tumors grown for 2 weeks in
TgN(Tie2-GFP) mice. Scale bar, 120 m.receptors tested. Remarkably, when we coinjected these cells
together with N202 tumor cells (1:10 ratio; 5 × 104 MPCs) s.c.
in nude mice, we found that they gave rise to a large proportion
of the tumor α-SMA+ cells (45% ± 6% β-gal+; >550 α-SMA+
cells analyzed from four tumors) 2 weeks later (Figure 8B). No
β-gal+ cells were observed in tumors grown from the injection
of tumor cells alone (n = 3). The β-gal+ cells did not express
GFP at this time point of analysis, suggesting that the injected
cells shut off Tie2 expression while differentiating. We found
that the β-gal+ cells did not colocalize with CD31+ ECs, al-
though they often loosely surrounded small blood vessels, in
agreement with the expected arrangement of pericytes in tu-
mors (Morikawa et al., 2002). We obtained similar results byCANCER CELL : SEPTEMBER 2005using MPCs transduced ex vivo with a LV constitutively ex-
pressing GFP from a PGK-GFP expression cassette (Figure
8C). Taken together, these results strongly suggest that a rare
population of MPCs, characterized by the expression of Tie2
and CD13 and found within the tumor stroma, may represent
the major source of vascular mural cells in tumors.
Discussion
A distinct lineage of Tie2+ monocytes promotes
tumor vascularization
Our data provide evidence for the existence of a distinct mono-
cyte lineage, which we termed Tie2-expressing monocytes221
A R T I C L EFigure 8. Tie2+ mesenchymal progenitors gener-
ate tumor vessel pericytes
A: In vitro culture and characterization of MPCs,
isolated as in Figure 7 from tumors grown for 2
weeks in double transgenic TgN(lacZ/Tie2-GFP)
mice. Cells were counted at each passage (top
left graph). MPCs cultured for ten population
doublings were stained with X-gal to detect
β-galactosidase (β-gal) activity (bottom left
panel), or labeled with PE-conjugated antibod-
ies against Tie2, CD13, and Sca-1, for FACS
analysis (histogram plots in the middle; filled his-
togram is the IgG isotype control), or lysed for
RNA extraction and RT-PCR analysis of VEGF-A,
bFGF, EGF, PDGF-B, HGF, IGF-I, IGF-II, FGFR-1,
FGFR-4, EGFR, PDGFR-α, c-Met, IGFR-II, and
GAPDH transcripts (right panel). RNA from the
other indicated cell cultures was included for
comparison in the RT-PCR analysis.
B: Confocal IF analysis of β-gal, NG2, or GFP
(green), α-SMA or CD31 (red), and TP3 (blue)
staining of tumors originated by the injection of
N202 cells alone or N202 cells together with
MPCs (10:1 ratio) in nude mice and analyzed 2
weeks later. The injected MPCs differentiated
into β-gal+α-SMA+ pericytes, which often sur-
rounded CD31+ blood vessels (arrows). Scale
bar, 120 m.
C: Confocal IF analysis for GFP (green) and
α-SMA (red) of a tumor originated by the injec-
tion of N202 cells together with MPCs (10:1 ra-
tio), isolated as in A and transduced by a PGK-
GFP LV, in nude mice and analyzed 2 weeks
later. Scale bar, 120 m.(TEMs), endowed with proangiogenic activity and required to
promote tumor vascularization. These cells were identified in
tumors and in the PB as a fraction of CD11b+ myeloid cells
specifically expressing Tie2, a receptor tyrosine kinase pre-
viously known to be restricted to ECs. Although the functional
role of Tie2 expression has been elucidated in HSCs (Yano et
al., 1997; Arai et al., 2004), its occurrence in a distinct subset
of monocytes has only been recently described (De Palma et
al., 2003a).
We identified TEMs using a sensitive reporter system based
on LV-mediated transduction and transgenesis of transcription
regulatory sequences from the Tie2/Tek gene driving GFP ex-
pression. We observed consistent frequency of TEMs in the PB
and BM of several transgenic lines and in mice transplanted222with ex vivo-transduced HSCs and verified Tie2 receptor ex-
pression in the GFP-expressing cells, indicating that the ex-
pression pattern of the Tie2-GFP transgene faithfully repro-
duced that of the endogenous locus with little influence of the
vector integration site.
Evidence supporting the existence of a distinct TEM lineage
was obtained from GCV-treated Tie2-tk mice and transplant
recipients of GCV-treated Tie2-tk BM. In these studies, the ma-
jority of the Tie2+ HCs were eliminated from the BM without
obvious effects on hematopoiesis, strongly suggesting that the
GCV-sensitive Tie2+ HCs were distinct from multipotent HPCs
and HSCs. Because GCV only kills proliferating tk-expressing
cells, these findings also imply that primitive Tie2+ HSCs must
be quiescent or selectively GCV resistant and that they mustCANCER CELL : SEPTEMBER 2005
A R T I C L Eturn off Tie2 expression in their clonogenic progeny. This sce-
nario is in agreement with a recent study that showed that
5-FU, an agent that selectively kills proliferating cells, pre-
served the Tie2+ HSCs in the BM stem cell niche (Arai et al.,
2004). On the other hand, the authors observed that 5-FU
treatment eliminated a population of Tie2+ HCs in the BM vas-
cular zone. Since the specific elimination of Tie2+ HCs did not
detrimentally affect hematopoiesis in our experimental models,
it is tempting to speculate that these 5-FU-sensitive Tie2+ HCs
represented the BM reservoir of committed TEM precursors.
Additional evidence for the existence of a distinct lineage of
TEMs was provided by the delayed recovery of tumor growth
observed after halting GCV treatment of Tie2-tk BMT mice.
This finding suggested that the GCV-resistant HCs, including
circulating and tumor-infiltrating monocyte/macrophages, were
not capable of acquiring a TEM phenotype in the tumors when
counterselection by GCV was relieved and that the TEM cell
pool had to be reconstituted in the BM from putative TEM
cell progenitors.
Our data also indicate that circulating TEMs are already
committed to a proangiogenic function. Since TEMs constitu-
tively circulate in PB but are not found in quiescent tissues,
they may respond to specific cues associated with tissue re-
modeling and angiogenesis to extravasate, possibly acquire a
specialized phenotype, and eventually exert their function. In-
terestingly, TEMs are a small fraction of the hematopoietic in-
filtrate found at sites of angiogenesis at steady state. It thus
appears that TEMs are short-lived effectors that are selectively
retrieved from a pool of circulating cells and are quickly ex-
hausted at angiogenesis sites. However, further studies are
needed to conclusively establish the developmental relation-
ship between circulating and tissue-homing TEMs.
Remarkably, TEM activity accounted for most of the proan-
giogenic activity of PB and tumor-infiltrating myeloid cells in
our experimental models. It is well established that TAMs exert
proangiogenic activity in tumors, although functional hetero-
geneity within this cell population has been documented (Pol-
lard, 2004). Whereas this heterogeneity may reflect modulation
of the monocyte/macrophage function between growth-pro-
moting and growth-inhibitory activities by the local environ-
ment, our data indicate the occurrence of a subset of these
cells specifically committed to a proangiogenic function. We
cannot rule out that the TEM population, which we have opera-
tionally defined and isolated according to the expression of a
combination of surface markers, may have some degree of
functional heterogeneity, which is commonly observed in other
HC subsets. Although the molecular bases of the proangio-
genic activity of TEMs need to be elucidated, the selective in-
volvement of these cells in angiogenesis makes them promis-
ing antitumor target candidates.
Proangiogenic TEMs, but not BM-derived EPCs,
are recruited to spontaneous and orthotopic tumors
and are required for tumor neovascularization
The specific recruitment and association of TEMs with the neo-
vasculature of spontaneous pancreatic adenocarcinomas and
human brain tumors grown orthotopically in mice highlighted
the general relevance of these cells in tumor angiogenesis. By
using gene marking approaches based on BMT, we did not find
evidence of BM-derived ECs and pericytes in these tumors, in
agreement with our previous findings in s.c. tumor grafts (DeCANCER CELL : SEPTEMBER 2005Palma et al., 2003a). Nevertheless, ad hoc mouse and tumor
models may enhance the recruitment of the elusive EPCs from
the BM. To force the mobilization of putative EPCs from the
BM and their incorporation into tumor vessels, we generated
transgenic mice in which EC proliferation and angiogenesis
could be specifically blocked by GCV administration. These
mice had a remarkable tumor-resistant phenotype, which was
not rescued by the transplantation of wild-type BM cells, indi-
cating that putative BM-derived EPCs could not restore angio-
genesis when the local supply of preexisting ECs was ham-
pered.
Our results and their interpretation differ from those of Lyden
et al., who showed that wild-type BMT rescued the angiogenic
defect of Id1+/−Id3−/− mice (Lyden et al., 2001). The authors
suggested that mobilization and recruitment of EPCs and
HPCs from the BM was impaired in Id mutant mice and that
this defect was responsible for the tumor-resistant Id mutant
phenotype. Id mutant mice display both deficiencies in EC re-
sponse to angiogenic stimuli and defective HC mobilization
from the BM (Ruzinova et al., 2003; Volpert et al., 2002; Be-
nezra et al., 2001). In one study, Id1−/− mice were paradoxically
more susceptible to skin carcinogenesis than wild-type mice,
and this effect was linked to the impaired recruitment of γδ T
cells to the tumors (Sikder et al., 2003). It is difficult to establish
whether the defective angiogenic phenotype of Id1+/−Id3−/−
mice is primarily due to cell-autonomous deficiencies in ECs,
rather than to the defective recruitment of HCs at sites of an-
giogenesis, or both. Because Id gene loss only impairs the
growth of some tumor types, Id-defective ECs may not be in-
herently incapable of undertaking angiogenesis. Indeed, in tu-
mor-prone transgenic mice that are affected by Id gene loss,
reduced tumor viability, rather than decreased tumor incidence
or improved survival have been observed (Ruzinova et al.,
2003; Li et al., 2004). Although BMT rescued tumor viability in
these mice, the contribution of BM-derived EPCs was esti-
mated to be low in these tumors, suggesting that tumor-
infiltrating BM-derived cells promoted the formation of func-
tional vessels mostly in a paracrine manner. Wild-type tumor-
infiltrating myeloid cells indeed express mitogens and matrix
remodeling factors, such as MMPs, which are downregulated
by Id gene disruption in ECs (Ruzinova et al., 2003). Based on
these data, one can speculate that Id mutant HCs may have
altered tumor-homing and/or proangiogenic capacity, and that
these defects largely contribute to the angiogenesis-defective
and tumor-resistant Id mutant phenotype.
These observations and our results support the emerging
paradigm that BM-derived cells recruited to tumors and other
sites of angiogenesis, rather than providing a source of building
blocks for “postnatal vasculogenesis,” comprise distinct HC
subsets that promote angiogenesis by secreting or mobilizing
growth factors, or by physically cooperating with ECs in mak-
ing new blood vessels, for instance, by drilling “tunnels” in the
extracellular matrix and supporting the migration of vascular
cells. Because TEMs share some markers with ECs, closely
associate with them in newly formed vessels, and exert a pro-
angiogenic activity, they may have been referred to as “EPCs”
in some previous studies. However, if the term “EPC” indicates
a cell type capable of robust differentiation into bona fide ECs
and effective incorporation within the vascular endothelium,
this term should not be used to denote cell types that maintain
a hematopoietic phenotype throughout their life span and exert223
A R T I C L Etheir function perivascularly, possibly by providing a temporary
scaffold or paracrine support for endothelialization. Intriguingly,
CD11b+ myeloid cells were recently reported to infiltrate avas-
cular tumors (Okamoto et al., 2005), suggesting that HCs en-
gage in the angiogenic process before the occurrence of the
angiogenic switch. Mature HCs likely represent the preeminent
cells in the body endowed with the ability to migrate within
tissues—even in hypoxic conditions—and with the capacity to
modify the extracellular matrix and amplify paracrine signals.
It has been established that orthotopic gliomas initially grow
by exploiting the preexistent vasculature in a process known
as “vessel cooption.” The coopted blood vessels eventually re-
gress, leading to a secondarily avascular tumor characterized
by massive tumor cell loss. Tumor viability and growth are be-
latedly rescued by de novo vessel formation through an “angio-
genic phase,” a process primarily occurring at the tumor pe-
riphery (Holash et al., 1999). Remarkably, elimination of TEMs
completely prevented the angiogenic phase of human gliomas
grafted in the mouse brain and caused widespread tumor ne-
crosis and regression. Consistent with these findings, purified
TEMs, and not other tumor-derived myeloid cells, triggered the
early phases of tumor vascularization in s.c. models. Thus,
TEMs may be pivotal effectors of the angiogenic switch, and
their recruitment from the circulation appears to be a rate-limit-
ing factor for tumor growth.
Tumor Tie2+ mesenchymal progenitors
generate tumor pericytes
Besides ECs and TEMs, we found that a rare population of
CD13+ cells in the tumors expressed Tie2. This cell population
was highly enriched in MPCs capable of long-term self-renewal
and differentiation into different mesodermal lineages in vitro.
Remarkably, these cells generated a large fraction of the tumor
pericytes in transplantation experiments in vivo. In vitro, these
MPCs expressed VEGF-A and bFGF, suggesting that they may
also modulate the activity of ECs in the angiogenic process. In
agreement with this hypothesis, it is known that tumor perivas-
cular cells produce VEGF, which can serve as a survival factor
for ECs (Jain, 2003).
The tissue origin of tumor pericytes is obscure. It has been
proposed that mesenchymal cells at the tumor-host interface
are triggered by the tumor microenvironment to differentiate
first into myofibroblasts, and then into pericyte-like cells (Jain,
2003). Some recent reports have proposed a BM origin of tu-
mor pericytes and myofibroblasts in the adult (Rajantie et al.,
2004; Direkze et al., 2004). Our gene marking and BMT studies
seem, however, to indicate that the vast majority of pericyte
progenitors are recruited to tumors from the local environment,
and not from the BM.
The Tie2+CD13+ MPCs shut off expression of Tie2 upon
acquisition of a “mature” pericyte phenotype in vivo. Although
one recent study reported expression of Tie2 by a subset of
mural cell progenitors in the rat aorta (Iurlaro et al., 2003), a
role of Tie2-expressing pericyte progenitors in tumor angiogen-
esis has never been described. Consistent with our findings,
it has been shown that angiopoietin-1 (Ang-1) stimulated the
migration of Tie2+ mesenchymal cells in matrigel plugs in the
presence of VEGF (Metheny-Barlow et al., 2004). Furthermore,
brain tumors overexpressing Ang-1 exhibited abnormal infiltra-
tion of mesenchymal cells and pericytes (Winkler et al., 2004).
Remarkably, either the pharmacological blockade of Ang-1/224Tie2 signaling by using a Tie2-blocking antibody or the down-
regulation of Ang-1 expression in tumor cells by RNA interfer-
ence reverted this phenotype. Together, these observations
suggest that Ang-1 may promote the recruitment of Tie2-
expressing pericyte precursors to newly forming vessels, al-
though future studies will need to address whether Ang-1 directly
acts on these precursors to exert this activity. It is tempting
to speculate that a similar mechanism may also regulate the
recruitment of TEMs to sites of angiogenesis.
Tie2 expression by proangiogenic cells of diverse origin:
Implications for anticancer therapies
In conclusion, expression of Tie2 in tumors identifies an inte-
grated system of different cell types: ECs, TEMs, and vascular
mural cell progenitors, which are all specifically involved in an-
giogenesis. The combined targeting of these three cell types by
a suicide gene may well explain the dramatic tumor resistance
observed in the Tie2-tk transgenic mice in our studies. Al-
though future work is needed to establish whether the angio-
poietin/Tie2 signaling pathway plays a critical role in each of
these cell types, or even integrates their activities in the angio-
genic process, our observations, together with the results ob-
tained in preclinical testing of anticancer drugs that interfere
with angiopoietin/Tie2 signaling (Oliner et al., 2004), validate
the Tie2 receptor as a prime target of antiangiogenic therapies.
Since also quiescent vessels express Tie2, the design of thera-
peutic strategies aimed at targeting this receptor should be
carefully evaluated. Nevertheless, this concern is alleviated by
the observation that Tie2 expression is upregulated at sites of
de novo vessel formation (Peters et al., 2004). The combined
targeting of the Tie2-expressing cells in tumors—TEMs of
hematopoietic origin, pericyte progenitors of mesenchymal ori-
gin, and ECs—should dramatically improve the efficacy of can-
cer therapies.
Experimental procedures
Lentiviral vector constructs
The Tie2p/e-GFP, Tie2p/e-tk.IRES.GFP, and PGKp-GFP lentiviral transfer
vectors were previously described; concentrated VSV.G-pseudotyped LV
stocks were produced and titered as described (De Palma et al., 2003a,
2003b).
Mice
C57BL/6, FVB, nude (nu/nu), and SCID mice were purchased from Charles
River Laboratory (Calco, Milan, Italy); RIP-Tag2 mice were obtained from
the NCI-Frederick Mouse Repository (Frederick, MD). All procedures were
performed according to protocols approved by the Animal Care and Use
Committee of the Fondazione San Raffaele del Monte Tabor and communi-
cated to the Ministry of Health and local authorities according to the Ital-
ian law.
Generation of transgenic mice by lentiviral vectors
Transgenic mice were generated using LVs as described by Lois et al.
(2002). All transgenic lines were generated in the FVB background. Methods
are described as Supplemental Experimental Procedures.
Tumor studies and in vivo matrigel assays
N202.1A cells (5–10 × 105) were injected s.c. in syngenic FVB mice, and
tumors were grown for 3–8 weeks. Tumor size was determined by caliper
measurements, and tumor volume was calculated by a rational ellipse for-
mula (m1 × m1 × m2 × 0.5236, where m1 is the shorter axis and m2 is the
longer axis). To obtain tumor cell suspensions, tumors grown s.c. in mice
for at least 2 weeks were processed mechanically and by collagenase di-
gestion for 2 hr at 37°, then filtered and prepared for FACS analysis. ToCANCER CELL : SEPTEMBER 2005
A R T I C L Einduce orthotopic brain tumors in nude BMT mice, 2 × 105 human glioblas-
toma multiforme-derived neural stem cells (line 0627) or human glioma U87
cells were delivered into the right striatum (0.2 l/min) of deeply anesthe-
tized (Avertin) adult female mice by stereotactic injection (Galli et al., 2004;
Winkler et al., 2004). Tumor growth was monitored by MRI (see Figure S6).
For matrigel plug assays, we used matrigel matrix with reduced growth
factor composition (Becton-Dickinson). Matrigel plugs were obtained by
mixing 250 l of matrigel with 250 l of IMDM medium containing 0.7–2.5 ×
105 cells and by injecting the resultant cell suspension s.c. in male nude
mice. To quantify angiogenesis, three to five sections of each of two to seven
tumors or matrigel plugs per group were immunostained for CD31 or CD34
and scanned at ×200 magnification by a confocal microscope to identify
regions of high vascular density. We then measured the vascular area by
computer-assisted digital image analysis, as described (Wild et al., 2000),
or counted individual EC marker-positive vessels (or TO-PRO-3+ nuclei be-
longing to vessels) in at least five ×200 fields from each section. Counts
were averaged to determine the vascular area or the vessel density. In all
studies, values are expressed as mean ± SEM. Differences were considered
statistically significant at p < 0.05 (unpaired Student’s t test).
FACS, IF staining, and confocal microscopy
Methods are available as Supplemental Experimental Procedures.
BMT
Six-week-old C57BL/6, FVB, TgN(Tie2-tk), or nude mice were killed with
CO2, and their BM was harvested by flushing the femurs and the tibias. Lin−
cells (106) (purified using a kit from StemCell Technologies) or 107 total BM
cells were infused into the tail vein of lethally irradiated (975 cGy) 6- to
8-week-old mice or injected into the peritoneum of lethally irradiated (625
cGy) 8-day-old RIP-Tag2 mice. Lin− cells were transduced by LVs as de-
scribed (De Palma et al., 2003a). Full hematopoietic reconstitution of trans-
planted mice was assessed by FACS analysis of PB, and CFC assays and
PCR of the GFP sequence on BM cells 6–12 weeks after the transplant, as
described (De Palma et al., 2003a).
Isolation, characterization, expansion, and differentiation of MPCs
Methods are available as Supplemental Experimental Procedures.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
one table, and six figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/8/3/211/DC1/.
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